ORIGINAL ARTICLE |
|
Year : 2016 | Volume
: 37
| Issue : 4 | Page : 271-277 |
|
Oxaliplatin-related neuropathy in Indian patients – no difference between generic and original molecules
Bhawna Sirohi1, Vikas Ostwal1, Shaheenah Dawood2, Gilberto Lopes3, Sanjay Talole4, Chaitali Nashikkar5, Shailesh Shrikhande5
1 Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India 2 Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates 3 Sylvester Comprehensive Cancer Center at the University of Miami, FL, United States, and Oncoclínicas Group, Brazil 4 Department of Biostatistics, Tata Memorial Centre, Mumbai, Maharashtra, India 5 Department of GI and HPB Surgery, Tata Memorial Centre, Mumbai, Maharashtra, India
Correspondence Address:
Bhawna Sirohi Departments of Medical Oncology, Tata Memorial Centre, Parel, Mumbai - 400 012, Maharashtra India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0971-5851.195745
|
|
Background: Oxaliplatin-induced neuropathy is a dose-limiting toxicity that significantly affects patients' quality of life. The aim of this study was to compare its occurrence between a generic versus the original molecule in Indian patients. Materials and Methods: Between August 2012 and July 2013, 163 patients receiving oxaliplatin were prospectively enrolled. A data recording form was used in the clinic to record detailed information. Results: The median age of patients was 55 years (range, 19–79). Chemotherapy regimens used included: capecitabine, oxaliplatin (59), epirubicin, oxaliplatin, and capecitabine (20), docetaxel, oxaliplatin, and capecitabine (11), 5-FU, leucovorin, oxaliplatin (9), and gemcitabine-oxaliplatin (64). The median cumulative dose of oxaliplatin was 780 mg/m2. Eighty patients received the original version and 83 the generic one. Overall, 63 patients (38%) developed neuropathy. There was no significant difference in the incidence of neuropathy between the two forms of oxaliplatin used (P = 0.50). Forty-nine percent of female patients had neuropathy as compared to 30% of male patients (P = 0.014). Older patients had a trend toward a higher incidence of neuropathy: 44% of patients above age fifty developed neuropathy compared to 30% of patients younger than 50 (P = 0.06). Conclusion: This is the first study to specifically show that neuropathy rates do not vary with the use of generic versus original oxaliplatin. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|